for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PerkinElmer, Inc.

PKI

Latest Trade

124.40USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

62.91

 - 

134.39

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
124.40
Open
--
Volume
--
3M AVG Volume
18.46
Today's High
--
Today's Low
--
52 Week High
134.39
52 Week Low
62.91
Shares Out (MIL)
111.81
Market Cap (MIL)
14,209.39
Forward P/E
--
Dividend (Yield %)
0.22

Next Event

Q3 2020 PerkinElmer Inc Earnings Release

Latest Developments

More

Perkinelmer Sets Regular Quarterly Dividend Of $0.07 Per Share

PerkinElmer Sees Q3 Reported Revenue Growth Of ~35%

Perkinelmer Launches DA 7350 Instrument & Cloud-Based Software For Quality Control In Food Production

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PerkinElmer, Inc.

PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.

Industry

Scientific & Technical Instr.

Contact Info

155 Federal St Ste 700

BOSTON, MA

02110-1727

United States

+1.781.6635776

http://www.perkinelmer.com/

Executive Leadership

Alexandros P Michas

Independent Non-Executive Chairman of the Board

Prahlad R. Singh

President, Chief Executive Officer, Director

James M. Mock

Chief Financial Officer, Senior Vice President

Deborah Butters

Chief Human Resource Officer, Senior Vice President

Joel S. Goldberg

Senior Vice President - Administration, General Counsel, Secretary

Key Stats

2.29 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.3K

2018

2.8K

2019

2.9K

2020(E)

3.3K
EPS (USD)

2017

2.900

2018

3.610

2019

4.100

2020(E)

5.548
Price To Earnings (TTM)
48.02
Price To Sales (TTM)
4.77
Price To Book (MRQ)
4.77
Price To Cash Flow (TTM)
27.10
Total Debt To Equity (MRQ)
66.43
LT Debt To Equity (MRQ)
54.76
Return on Investment (TTM)
5.27
Return on Equity (TTM)
4.51

Latest News

Latest News

PerkinElmer forecasts 12% rise in second-quarter revenue

Diagnostic kit maker PerkinElmer Inc <PKI.N> on Monday forecast a 12% rise in second-quarter revenue on better-than-expected demand for its COVID-19 testing products.

Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources

Medical diagnostic firm PerkinElmer Inc faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters.

BRIEF-PerkinElmer Says Got Subpoenas From Government Regarding Investigations Into Third Parties

* PERKINELMER - GOT SUBPOENAS FROM GOVERNMENT REGARDING INVESTIGATIONS INTO THIRD PARTIES Source text for Eikon: Further company coverage:

BRIEF-Perkinelmer Reports Q1 Adj EPS Of $0.67 From Continuing Operations

* PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020

BRIEF-FDA Provides Emergency Use Authorization To Perkinelmer For Serological Test To Identify Covid-19 Antibodies

* FDA PROVIDES EMERGENCY USE AUTHORIZATION TO PERKINELMER FOR SEROLOGICAL TEST TO IDENTIFY COVID-19 ANTIBODIES

BRIEF-Perkinelmer Approved A Modification To Director Compensation Program

* PERKINELMER - ON MARCH 30, BOARD APPROVED A MODIFICATION TO THE COMPANY’S DIRECTOR COMPENSATION PROGRAM

BRIEF-Perkinelmer Says Has Expanded Production Capacity Of Its New Coronavirus RT-PCR Tests

* PERKINELMER - HAS EXPANDED PRODUCTION CAPACITY OF ITS EXTRACTION AND NEW CORONAVIRUS RT-PCR TESTS AT ITS GLOBAL FACILITIES - SEC FILING Source text: [https://bit.ly/2QO7Yh4] Further company coverage:

BRIEF-FDA Provides Emergency Use Authorization To Perkinelmer For Covid-19 Testing

* FDA PROVIDES EMERGENCY USE AUTHORIZATION TO PERKINELMER FOR COVID-19 TESTING

BRIEF-PerkinElmer Expects Q1 Revenue And EPS To Be Below Previous Guidance

* PERKINELMER - EXPECTS Q1 2020 REVENUE AND EARNINGS PER SHARE, BOTH ON A GAAP AND NON-GAAP BASIS, TO BE BELOW COMPANY'S PREVIOUSLY COMMUNICATED GUIDANCE

BRIEF-PerkinElmer Elects Michel Vounatsos To Its Board Of Directors

* PERKINELMER ELECTS MICHEL VOUNATSOS TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

UPDATE 1-PerkinElmer raises 2018 forecasts as 1st-qtr profit beats Street

Laboratory equipment maker PerkinElmer posted a slightly higher-than-expected first-quarter profit on Monday and revised its full-year earnings forecast upward as sales grew in both of its business units.

PerkinElmer first-quarter profit beats Street view

Laboratory equipment maker PerkinElmer on Monday reported slightly higher-than-expected first-quarter profit and revenue and raised its full-year earnings forecast as sales grew in both of its business units.

BRIEF-PerkinElmer Appoints James Mock As Chief Financial Officer

* PERKINELMER INC - ANDY WILSON WILL REMAIN WITH COMPANY AS AN ADVISOR FOR AN INTERIM PERIOD Source text for Eikon: Further company coverage:

BRIEF-PerkinElmer Collaborates With Helix In Exome Based Personal Genomics

* PERKINELMER COLLABORATES WITH HELIX TO DRIVE INNOVATION IN EXOME-BASED PERSONAL GENOMICS

BRIEF-Perkinelmer Inc Files Prospectus Supplement Related To A Potential Senior Notes Offering

* PERKINELMER INC FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL SENIOR NOTES OFFERING - SEC FILING Source text: (https://bit.ly/2q3PNq6) Further company coverage:

BRIEF-RHS Enters Deal For Perkinelmer, Inc To Buy All Shares Of Co For $0.28 Per Share

* ENTERS SCHEME IMPLEMENTATION AGREEMENT FOR PERKINELMER, INC TO BUY ALL SHARES OF CO FOR $0.28 PER SHARE

BRIEF-Perkinelmer Reports Q4 GAAP Loss Per Share From Cont Ops of $0.35

* Q4 ADJUSTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.97

PerkinElmer profit, 2018 forecast top Wall Street estimates

Laboratory equipment maker PerkinElmer Inc <PKI.N> on Thursday reported higher-than-expected fourth quarter sales and profit and issued an initial 2018 earnings forecast that surpassed Wall Street estimates.

PerkinElmer profit, 2018 forecast top Wall Street estimates

Laboratory equipment maker PerkinElmer Inc on Thursday reported higher-than-expected fourth quarter sales and profit and issued an initial 2018 earnings forecast that surpassed Wall Street estimates.

BRIEF-Perkinelmer Q4 Adjusted Earnings Per Share $0.97 From Continuing Operations

* PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up